Brenda M Sandmaier

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7069826/publications.pdf

Version: 2024-02-01

394	26,988	9264 74	6654 156
papers	citations	h-index	g-index

398	398	398	13413
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood, 2005, 106, 2912-2919.	1.4	2,427
2	HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide. Biology of Blood and Marrow Transplantation, 2008, 14, 641-650.	2.0	1,525
3	Defining the Intensity of Conditioning Regimens: Working Definitions. Biology of Blood and Marrow Transplantation, 2009, 15, 1628-1633.	2.0	1,419
4	Reduced Mortality after Allogeneic Hematopoietic-Cell Transplantation. New England Journal of Medicine, 2010, 363, 2091-2101.	27.0	1,335
5	Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood, 2001, 97, 3390-3400.	1.4	1,306
6	Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood, 2003, 102, 756-762.	1.4	531
7	Conditioning regimens for hematopoietic cell transplantation: one size does not fit all. Blood, 2014, 124, 344-353.	1.4	437
8	Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood, 2003, 102, 827-833.	1.4	432
9	Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood, 2003, 101, 1620-1629.	1.4	424
10	Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood, 2003, 102, 3447-3454.	1.4	382
11	Comorbidity and Disease Statusâ€“Based Risk Stratification of Outcomes Among Patients With Acute Myeloid Leukemia or Myelodysplasia Receiving Allogeneic Hematopoietic Cell Transplantation. Journal of Clinical Oncology, 2007, 25, 4246-4254.	1.6	380
12	Comorbidity-Age Index: A Clinical Measure of Biologic Age Before Allogeneic Hematopoietic Cell Transplantation. Journal of Clinical Oncology, 2014, 32, 3249-3256.	1.6	361
13	Cord-Blood Transplantation in Patients with Minimal Residual Disease. New England Journal of Medicine, 2016, 375, 944-953.	27.0	352
14	Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. Blood, 2013, 122, 1813-1821.	1.4	325
15	HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood, 2003, 102, 2021-2030.	1.4	320
16	Graft-Versus-Tumor Effects After Allogeneic Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning. Journal of Clinical Oncology, 2005, 23, 1993-2003.	1.6	312
17	Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study. Lancet Haematology,the, 2016, 3, e119-e127.	4.6	307
18	Hematopoietic cell transplantationâ€“specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. Blood, 2007, 110, 4606-4613.	1.4	292

#	Article	IF	Citations
19	Long-term Outcomes Among Older Patients Following Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation for Advanced Hematologic Malignancies. JAMA - Journal of the American Medical Association, 2011, 306, 1874.	7.4	274
20	Five-Year Follow-Up of Patients With Advanced Chronic Lymphocytic Leukemia Treated With Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning. Journal of Clinical Oncology, 2008, 26, 4912-4920.	1.6	257
21	Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood, 2003, 102, 3912-3918.	1.4	255
22	Comparison of Outcomes of HLA-Matched Related, Unrelated, or HLA-Haploidentical Related Hematopoietic Cell Transplantation following Nonmyeloablative Conditioning for Relapsed or Refractory Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation, 2008, 14, 1279-1287.	2.0	251
23	Risks and outcomes of idiopathic pneumonia syndrome after nonmyeloablative and conventional conditioning regimens for allogeneic hematopoietic stem cell transplantation. Blood, 2003, 102, 2777-2785.	1.4	249
24	Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood, 2004, 104, 3535-3542.	1.4	248
25	Treatment for Acute Myelogenous Leukemia by Low-Dose, Total-Body, Irradiation-Based Conditioning and Hematopoietic Cell Transplantation From Related and Unrelated Donors. Journal of Clinical Oncology, 2006, 24, 444-453.	1.6	243
26	Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: A matched control study. Biology of Blood and Marrow Transplantation, 2002, 8, 512-520.	2.0	236
27	Hematopoietic cell transplantationâ€comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation. Cancer, 2008, 112, 1992-2001.	4.1	233
28	Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood, 2004, 104, 2254-2262.	1.4	226
29	Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. Blood, 2002, 99, 1978-1985.	1.4	220
30	Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning for Advanced Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 2005, 23, 3819-3829.	1.6	214
31	Graft-Versus-Host Disease and Graft-Versus-Tumor Effects After Allogeneic Hematopoietic Cell Transplantation. Journal of Clinical Oncology, 2013, 31, 1530-1538.	1.6	197
32	Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia. Journal of Clinical Oncology, 2010, 28, 2859-2867.	1.6	191
33	Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Relapsed, Refractory, and Transformed Indolent Non-Hodgkin's Lymphoma. Journal of Clinical Oncology, 2008, 26, 211-217.	1.6	186
34	Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia. Blood, 2008, 111, 446-452.	1.4	181
35	Hematopoietic Cell Transplantation as Curative Therapy for Idiopathic Myelofibrosis, Advanced Polycythemia Vera, and Essential Thrombocythemia. Biology of Blood and Marrow Transplantation, 2007, 13, 355-365.	2.0	174
36	Allogeneic hematopoietic cell transplantation after conditioning with 131Iâ€“anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome. Blood, 2009, 114, 5444-5453.	1.4	161

#	Article	IF	Citations
37	Survival, Nonrelapse Mortality, and Relapse-Related Mortality After Allogeneic Hematopoietic Cell Transplantation: Comparing 2003â€“2007 Versus 2013â€“2017 Cohorts. Annals of Internal Medicine, 2020, 172, 229.	3.9	157
38	Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood, 2007, 110, 2744-2748.	1.4	156
39	Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients. Blood, 2004, 103, 78-84.	1.4	151
40	Efficacy of a Viral Load-Based, Risk-Adapted, Preemptive Treatment Strategy for Prevention of Cytomegalovirus Disease after Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2012, 18, 1687-1699.	2.0	145
41	Reduced-Intensity Conditioning followed by Allogeneic Hematopoietic Cell Transplantation for Adult Patients with Myelodysplastic Syndrome and Myeloproliferative Disorders. Biology of Blood and Marrow Transplantation, 2008, 14, 246-255.	2.0	133
42	The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation. Blood, 2012, 119, 2657-2664.	1.4	133
43	Invasive aspergillosis before allogeneic hematopoietic stem cell transplantation: 10-year experience at a single transplant center. Biology of Blood and Marrow Transplantation, 2004, 10, 494-503.	2.0	132
44	In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clinic Proceedings, 2015, 90, 996-1000.	3.0	128
45	The cumulative burden of double-stranded DNA virus detection after allogeneic HCT is associated with increased mortality. Blood, 2017, 129, 2316-2325.	1.4	126
46	Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. Blood, 2004, 103, 790-795.	1.4	124
47	Vaccination with TheratopeÂ® (STn-KLH) as treatment for breast cancer. Expert Review of Vaccines, 2004, 3, 655-663.	4.4	118
48	Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic Leukemia: Relapse-Free Survival Is Determined by Karyotype and Comorbidities. Biology of Blood and Marrow Transplantation, 2011, 17, 908-915.	2.0	113
49	Outcomes among Patients with Recurrent High-Risk Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2007, 13, 1160-1168.	2.0	110
50	Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting. Blood, 2009, 113, 3383-3391.	1.4	106
51	Decreased transfusion requirements for patients receiving nonmyeloablative compared with conventional peripheral blood stem cell transplants from HLA-identical siblings. Blood, 2001, 98, 3584-3588.	1.4	101
52	Comparison of ARF after myeloablative and nonmyeloablative hematopoietic cell transplantation. American Journal of Kidney Diseases, 2005, 45, 502-509.	1.9	99
53	Results of a phase 1 study of quizartinib as maintenance therapy in subjects with acute myeloid leukemia in remission following allogeneic hematopoietic stem cell transplant. American Journal of Hematology, 2018, 93, 222-231.	4.1	99
54	Nonâ€myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large Bâ€cell lymphoma: a multicentre experience. British Journal of Haematology, 2008, 143, 395-403.	2.5	97

#	Article	IF	Citations
55	Immunologic recovery after hematopoietic cell transplantation with nonmyeloablative conditioning. Experimental Hematology, 2003, 31, 941-952.	0.4	96
56	Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia. Haematologica, 2011, 96, 1113-1120.	3.5	95
57	Who is fit for allogeneic transplantation?. Blood, 2010, 116, 4762-4770.	1.4	93
58	Incidence, risk factors, and outcomes of sclerosis in patients with chronic graft-versus-host disease. Blood, 2013, 121, 5098-5103.	1.4	93
59	EASIX in patients with acute graft-versus-host disease: a retrospective cohort analysis. Lancet Haematology,the, 2017, 4, e414-e423.	4.6	92
60	Non-myeloablative allografting from human leucocyte antigen-identical sibling donors for treatment of acute myeloid leukaemia in first complete remission. British Journal of Haematology, 2003, 120, 281-288.	2.5	90
61	Allogeneic Hematopoietic Cell Transplantation for Metastatic Renal Cell Carcinoma after Nonmyeloablative Conditioning. Clinical Cancer Research, 2004, 10, 7799-7811.	7.0	89
62	Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. Blood Advances, 2019, 3, 1826-1836.	5.2	89
63	Reduced Incidence of Acute and Chronic Graft-versus-Host Disease with the Addition of Thymoglobulin to a Targeted Busulfan/Cyclophosphamide Regimen. Biology of Blood and Marrow Transplantation, 2006, 12, 573-584.	2.0	88
64	Bismuth 213â€“labeled anti-CD45 radioimmunoconjugate to condition dogs for nonmyeloablative allogeneic marrow grafts. Blood, 2002, 100, 318-326.	1.4	86
65	Timing and severity of community acquired respiratory virus infections after myeloablative versus non-myeloablative hematopoietic stem cell transplantation. Haematologica, 2009, 94, 1101-1108.	3.5	86
66	Failure-free survival after initial systemic treatment of chronic graft-versus-host disease. Blood, 2014, 124, 1363-1371.	1.4	86
67	Characterization of Monoclonal Antibodies That Recognize Canine CD34. Blood, 1998, 91, 1977-1986.	1.4	85
68	Acute Renal Failure after Nonmyeloablative Hematopoietic Cell Transplantation. Journal of the American Society of Nephrology: JASN, 2004, 15, 1868-1876.	6.1	84
69	Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial. Lancet Haematology,the, 2019, 6, e409-e418.	4.6	84
70	Unrelated Donor Granulocyte Colony-Stimulating Factorâ€“Mobilized Peripheral Blood Mononuclear Cell Transplantation after Nonmyeloablative Conditioning: The Effect of Postgrafting Mycophenolate Mofetil Dosing. Biology of Blood and Marrow Transplantation, 2006, 12, 454-465.	2.0	83
71	Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality. Blood, 2014, 124, 287-295.	1.4	83
72	Total body irradiation dose and risk of subsequent neoplasms following allogeneic hematopoietic cell transplantation. Blood, 2019, 133, 2790-2799.	1.4	81

#	Article	IF	Citations
73	Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial CD3+ T Cell Dose. Biology of Blood and Marrow Transplantation, 2013, 19, 949-957.	2.0	79
74	Transplantation of Allogeneic Peripheral Blood Stem Cells Mobilized by Recombinant Human Granulocyte Colony Stimulating Factor. Stem Cells, 1996, 14, 90-105.	3.2	77
75	Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60â€“75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study. Leukemia, 2019, 33, 2599-2609.	7.2	76
76	Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy. Blood Advances, 2019, 3, 3062-3069.	5.2	74
77	Thymic recovery after allogeneic hematopoietic cell transplantation with non-myeloablative conditioning is limited to patients younger than 60 years of age. Haematologica, 2011, 96, 298-306.	3.5	71
78	Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia. Biology of Blood and Marrow Transplantation, 2018, 24, 726-733.	2.0	71
79	The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia. Blood Advances, 2019, 3, 670-680.	5.2	71
80	Decreased Rejection and Improved Survival of First and Second Marrow Transplants for Severe Aplastic Anemia (A 26-Year Retrospective Analysis). Blood, 1998, 92, 2742-2749.	1.4	70
81	Effect of Conditioning Regimen Intensity on CMV Infection in Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2009, 15, 694-703.	2.0	70
82	EASIX and mortality after allogeneic stem cell transplantation. Bone Marrow Transplantation, 2020, 55, 553-561.	2.4	70
83	Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome after conditioning with busulfan and fractionated total body irradiation is associated with low relapse rate but considerable nonrelapse mortality. Biology of Blood and Marrow Transplantation, 2002, 8, 161-169.	2.0	66
84	Selective T-cell ablation with bismuth-213â€“labeled anti-TCRÎ±Î² as nonmyeloablative conditioning for allogeneic canine marrow transplantation. Blood, 2003, 101, 5068-5075.	1.4	65
85	Nonmyeloablative Hematopoietic Cell Transplantation. Annals of the New York Academy of Sciences, 2001, 938, 328-339.	3.8	65
86	Reduced-Intensity Conditioning for Unrelated Donor Progenitor Cell Transplantation: Long-Term Follow-Up of the First 285 Reported to the National Marrow Donor Program. Biology of Blood and Marrow Transplantation, 2007, 13, 844-852.	2.0	65
87	Outcomes of hematopoietic cell transplantation using donors or recipients with inherited chromosomally integrated HHV-6. Blood, 2017, 130, 1062-1069.	1.4	65
88	Reagents for Astatination of Biomolecules. 6. An Intact Antibody Conjugated with a Maleimido-closo-Decaborate(2-) Reagent via Sulfhydryl Groups Had Considerably Higher Kidney Concentrations than the Same Antibody Conjugated with an Isothiocyanato-closo-Decaborate(2-) Reagent via Lysine Amines. Bioconjugate Chemistry, 2012, 23, 409-420.	3.6	62
89	Design and Validation of an Augmented Hematopoietic Cell Transplantation-Comorbidity Index Comprising Pretransplant Ferritin, Albumin, and Platelet Count for Prediction of Outcomes after Allogeneic Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 1418-1424.	2.0	62
90	Decreased Serum Albumin as a Biomarker for SevereÂAcute Graft-versus-Host Disease after Reduced-Intensity Allogeneic Hematopoietic CellÂTransplantation. Biology of Blood and Marrow Transplantation, 2011, 17, 1594-1601.	2.0	60

#	Article	IF	Citations
91	C19orf48Encodes a Minor Histocompatibility Antigen Recognized by CD8+ Cytotoxic T Cells from Renal Cell Carcinoma Patients. Clinical Cancer Research, 2008, 14, 5260-5269.	7.0	59
92	Feasibility of Allogeneic Hematopoietic Stem Cell Transplantation for Autoimmune Disease: Position Statement from a National Institute of Allergy and Infectious Diseases and National Cancer Instituteâ€"Sponsored International Workshop, Bethesda, MD, March 12 and 13, 2005. Biology of Blood and Marrow Transplantation, 2005, 11, 862-870.	2.0	56
93	Failure-free survival after second-line systemic treatment of chronic graft-versus-host disease. Blood, 2013, 121, 2340-2346.	1.4	55
94	Radiolabeled Anti-CD45 Antibody with Reduced-Intensity Conditioning and Allogeneic Transplantation for Younger Patients with Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome. Biology of Blood and Marrow Transplantation, 2014, 20, 1363-1368.	2.0	54
95	Contributions of a Highly Conserved VH/VL Hydrogen Bonding Interaction to scFv Folding Stability and Refolding Efficiency. Biophysical Journal, 1998, 75, 1473-1482.	0.5	53
96	Impact of Acute Kidney Injury on Long-Term Mortality after Nonmyeloablative Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2008, 14, 309-315.	2.0	52
97	What Is the Role for Donor Natural Killer Cells after Nonmyeloablative Conditioning?. Biology of Blood and Marrow Transplantation, 2009, 15, 580-588.	2.0	52
98	Durable donor engraftment after radioimmunotherapy using Î±-emitter astatine-211â€"labeled anti-CD45 antibody for conditioning in allogeneic hematopoietic cell transplantation. Blood, 2012, 119, 1130-1138.	1.4	52
99	Astatine-211 conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model. Blood, 2015, 125, 2111-2119.	1.4	52
100	Hematopoietic Cell Transplantation for Myelofibrosis: the Dynamic International Prognostic Scoring System Plus Risk Predicts Post-Transplant Outcomes. Biology of Blood and Marrow Transplantation, 2018, 24, 386-392.	2.0	52
101	Allogeneic haematopoietic cell transplantation for myelofibrosis in 30 patients 60â€"78â€ƒyears of age. British Journal of Haematology, 2011, 153, 76-82.	2.5	51
102	Mixed Hematopoietic Chimerism after Marrow Allografts Transplantation in the Ambulatory Care Setting. Annals of the New York Academy of Sciences, 1999, 872, 372-376.	3.8	50
103	Donor statin treatment protects against severe acute graft-versus-host disease after related allogeneic hematopoietic cell transplantation. Blood, 2010, 115, 1288-1295.	1.4	50
104	Differential L-Selectin Binding Activities of Human Hematopoietic Cell L-Selectin Ligands, HCELL and PSGL-1. Journal of Biological Chemistry, 2001, 276, 47623-47631.	3.4	48
105	HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with chronic myeloid leukemia. Biology of Blood and Marrow Transplantation, 2005, 11, 272-279.	2.0	48
106	Quantitative singleâ€particle digital autoradiography with Î±â€particle emitters for targeted radionuclide therapy using the iQID camera. Medical Physics, 2015, 42, 4094-4105.	3.0	48
107	Allogeneic transplantation for advanced acute myeloid leukemia: The value of complete remission. Cancer, 2017, 123, 2025-2034.	4.1	48
108	Biodistributions, Myelosuppression, and Toxicities in Mice Treated with an Anti-CD45 Antibody Labeled with the Î±-Emitting Radionuclides Bismuth-213 or Astatine-211. Cancer Research, 2009, 69, 2408-2415.	0.9	47

#	Article	IF	Citations
109	Cytopenias after day 28 in allogeneic hematopoietic cell transplantation: impact of recipient/donor factors, transplant conditions and myelotoxic drugs. Haematologica, 2011, 96, 1838-1845.	3.5	47
110	Treosulfan, Fludarabine, and 2-Gy Total Body Irradiation Followed by Allogeneic Hematopoietic Cell Transplantation in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia. Biology of Blood and Marrow Transplantation, 2014, 20, 549-555.	2.0	47
111	Impact of Donor Age on Outcome after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 105-112.	2.0	47
112	Unrelated Donor Status and High Donor Age Independently Affect Immunologic Recovery after Nonmyeloablative Conditioning. Biology of Blood and Marrow Transplantation, 2006, 12, 1176-1187.	2.0	46
113	The impact of donor type and ABO incompatibility on transfusion requirements after nonmyeloablative haematopoietic cell transplantation. British Journal of Haematology, 2010, 149, 101-110.	2.5	46
114	Central Nervous System Relapse in Adults with Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic StemÂCell Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 1767-1771.	2.0	46
115	Nonmyeloablative allogeneic hematopoietic cell transplantation. Haematologica, 2016, 101, 521-530.	3.5	46
116	Reduced intensity conditioned allograft yields favorable survival for older adults with Bâ€cell acute lymphoblastic leukemia. American Journal of Hematology, 2017, 92, 42-49.	4.1	46
117	TheratopeÂ® vaccine (STn-KLH). Expert Opinion on Biological Therapy, 2001, 1, 881-891.	3.1	45
118	Multiâ€centre validation of the prognostic value of the haematopoietic cell transplantationâ€•specific comorbidity index among recipient of allogeneic haematopoietic cell transplantation. British Journal of Haematology, 2015, 170, 574-583.	2.5	45
119	Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis. Cancer, 2016, 122, 3005-3014.	4.1	45
120	Allogeneic Hematopoietic Cell Transplantation Using Treosulfan-Based Conditioning for Treatment of Marrow Failure Disorders. Biology of Blood and Marrow Transplantation, 2017, 23, 1669-1677.	2.0	45
121	Allogeneic haematopoietic cell transplantation after nonmyeloablative conditioning in patients with Tâ€cell and natural killerâ€cell lymphomas. British Journal of Haematology, 2010, 150, 170-178.	2.5	44
122	Comparison of lung function after myeloablative and 2 Gy of total body irradiation-based regimens for hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation, 2005, 11, 288-296.	2.0	43
123	Association between Calcineurin Inhibitor Blood Concentrations and Outcomes after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2012, 18, 414-422.	2.0	42
124	Frequency of Allogeneic Hematopoietic Cell Transplantation Among Patients With High- or Intermediate-Risk Acute Myeloid Leukemia in First Complete Remission. Journal of Clinical Oncology, 2013, 31, 3883-3888.	1.6	42
125	Prognostic relevance of 'early-onset' graft-versus-host disease following non-myeloablative haematopoietic cell transplantation. British Journal of Haematology, 2005, 129, 381-391.	2.5	41
126	Outcome of Allogeneic Hematopoietic Cell Transplantation from HLA-Identical Siblings for Severe Aplastic Anemia in Patients Over 40 Years of Age. Biology of Blood and Marrow Transplantation, 2010, 16, 1411-1418.	2.0	41

#	Article	IF	Citations
127	Nonmyeloablative Unrelated Donor Hematopoietic Cell Transplantation to Treat Patients with Poor-Risk, Relapsed, or Refractory Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2007, 13, 423-432.	2.0	40
128	Impact of Recipient Statin Treatment on Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2010, 16, 1463-1466.	2.0	40
129	Comparable Outcomes after Nonmyeloablative Hematopoietic Cell Transplantation with Unrelated and Related Donors. Biology of Blood and Marrow Transplantation, 2007, 13, 1499-1507.	2.0	39
130	Low-Dose Total Body Irradiation and Fludarabine Conditioning for HLA Class I-Mismatched Donor Stem Cell Transplantation and Immunologic Recovery in Patients with Hematologic Malignancies: A Multicenter Trial. Biology of Blood and Marrow Transplantation, 2010, 16, 384-394.	2.0	39
131	Allogeneic Hematopoietic Cell Transplantation for Patients with Mixed Phenotype Acute Leukemia. Biology of Blood and Marrow Transplantation, 2016, 22, 1024-1029.	2.0	39
132	Extending Postgrafting Cyclosporine Decreases the Risk of Severe Graft-versus-Host Disease after Nonmyeloablative Hematopoietic Cell Transplantation. Transplantation, 2006, 81, 818-825.	1.0	38
133	Improving the Efficacy of Reduced Intensity Allogeneic Transplantation for Lymphoma using Radioimmunotherapy. Biology of Blood and Marrow Transplantation, 2006, 12, 697-702.	2.0	36
134	Costs of Allogeneic Hematopoietic Cell Transplantation Using Reduced Intensity Conditioning Regimens. Oncologist, 2014, 19, 639-644.	3.7	36
135	Minimal Identifiable Disease and the Role of Conditioning Intensity in Hematopoietic Cell Transplantation for Myelodysplastic Syndrome and Acute Myelogenous Leukemia Evolving from Myelodysplastic Syndrome. Biology of Blood and Marrow Transplantation, 2016, 22, 1227-1233.	2.0	36
136	Conditioning intensity and peritransplant flow cytometric MRD dynamics in adult AML. Blood, 2022, 139, 1694-1706.	1.4	36
137	Current status of hematopoietic stem cell transplantation after nonmyeloablative conditioning. Current Opinion in Hematology, 2005, 12, 435-443.	2.5	34
138	Current and Future Preparative Regimens for Bone Marrow Transplantation in Thalassemiaa. Annals of the New York Academy of Sciences, 1998, 850, 276-287.	3.8	33
139	A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation. Haematologica, 2014, 99, 1624-1631.	3.5	33
140	Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating Agents. Biology of Blood and Marrow Transplantation, 2017, 23, 1509-1514.	2.0	33
141	Impact of Pre-Transplant Comorbidities on the Rate of- and Mortality-Following Acute Graft-Versus-Host Disease (GVHD) After Allogeneic Hematopoietic Cell Transplantation (HCT). Blood, 2011, 118, 156-156.	1.4	33
142	Impact of unrelated donor status on the incidence and outcome of cytomegalovirus infections after non-myeloablative allogeneic stem cell transplantation. British Journal of Haematology, 2003, 123, 662-670.	2.5	31
143	Allografting after nonmyeloablative conditioning as a treatment after a failed conventional hematopoietic cell transplant. Biology of Blood and Marrow Transplantation, 2003, 9, 266-272.	2.0	31
144	Histology and Time to Progression Predict Survival for Lymphoma Recurring after Reduced-Intensity Conditioning and Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2011, 17, 1537-1545.	2.0	30

#	Article	IF	Citations
145	Number of Courses of Induction Therapy Independently Predicts Outcome after Allogeneic Transplantation for Acute Myeloid Leukemia in First Morphological Remission. Biology of Blood and Marrow Transplantation, 2015, 21, 373-378.	2.0	30
146	The Î±-emitter astatine-211 targeted to CD38 can eradicate multiple myeloma in a disseminated disease model. Blood, 2019, 134, 1247-1256.	1.4	30
147	Engraftment of early erythroid progenitors is not delayed after non-myeloablative major ABO-incompatible haematopoietic stem cell transplantation. British Journal of Haematology, 2002, 119, 740-750.	2.5	29
148	Salvage Allogeneic Hematopoietic Cell Transplantation with Fludarabine and Low-Dose Total Body Irradiation after Rejection of First Allografts. Biology of Blood and Marrow Transplantation, 2009, 15, 1314-1322.	2.0	29
149	Nonrelapse Mortality and Mycophenolic Acid Exposure in Nonmyeloablative Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2013, 19, 1159-1166.	2.0	29
150	Anti-CD45 radioimmunotherapy without TBI before transplantation facilitates persistent haploidentical donor engraftment. Blood, 2016, 127, 352-359.	1.4	29
151	Results of a Phase 1 Study of Quizartinib (AC220) As Maintenance Therapy in Subjects with Acute Myeloid Leukemia in Remission Following Allogeneic Hematopoietic Cell Transplantation. Blood, 2014, 124, 428-428.	1.4	29
152	Nonmyeloablative hematopoietic cell transplantation: status quo and future perspectives. Journal of Clinical Immunology, 2002, 22, 70-74.	3.8	28
153	Urinary Elafin and Kidney Injury in Hematopoietic Cell Transplant Recipients. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 12-20.	4.5	28
154	Evaluation of allogeneic transplantation in first or later minimal residual disease â€“ negative remission following adult-inspired therapy for acute lymphoblastic leukemia. Leukemia and Lymphoma, 2016, 57, 2109-2118.	1.3	28
155	Conditioning Intensity, Pre-Transplant Flow Cytometric Measurable Residual Disease, and Outcome in Adults with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation. Cancers, 2020, 12, 2339.	3.7	28
156	Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR. Leukemia, 2021, 35, 2076-2085.	7.2	28
157	Reagents for Astatination of Biomolecules. 4. Comparison of Maleimido-closo-Decaborate(2-) and meta-[²¹¹At]Astatobenzoate Conjugates for Labeling anti-CD45 Antibodies with [²¹¹At]Astatine. Bioconjugate Chemistry, 2009, 20, 1983-1991.	3.6	27
158	Prognostic impact of discordant results from cytogenetics and flow cytometry in patients with acute myeloid leukemia undergoing hematopoietic cell transplantation. Cancer, 2012, 118, 2411-2419.	4.1	27
159	Allogeneic Hematopoietic Cell Transplantation following Minimal Intensity Conditioning: Predicting Acute Graft-versus-Host Disease and Graft-versus-Tumor Effects. Biology of Blood and Marrow Transplantation, 2013, 19, 792-798.	2.0	27
160	Longâ€term sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Cancer, 2015, 121, 3709-3716.	4.1	27
161	Association of Distance from Transplantation Center and Place of Residence on Outcomes after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 1319-1323.	2.0	27
162	Relapse or progression after hematopoietic cell transplantation using nonmyeloablative conditioning: effect of interventions on outcome. Experimental Hematology, 2003, 31, 974-980.	0.4	26

#	Article	IF	Citations
163	cGMP production of astatine-211-labeled anti-CD45 antibodies for use in allogeneic hematopoietic cell transplantation for treatment of advanced hematopoietic malignancies. PLoS ONE, 2018, 13, e0205135.	2.5	26
164	Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia. Blood, 2021, 138, 387-400.	1.4	26
165	Radioimmunotherapy with Bismuth-213 as Conditioning for Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Dogs: A Dose Deescalation Study. Transplantation, 2004, 78, 352-359.	1.0	25
166	Steroids Versus Steroids Plus Additional Agent in Frontline Treatment of Acute Graft-versus-Host Disease: A Systematic Review and Meta-Analysis of Randomized Trials. Biology of Blood and Marrow Transplantation, 2016, 22, 1133-1137.	2.0	25
167	Comparing outcomes of matched related donor and matched unrelated donor hematopoietic cell transplants in adults with Bâ€Cell acute lymphoblastic leukemia. Cancer, 2017, 123, 3346-3355.	4.1	25
168	Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma. Haematologica, 2019, 104, 380-391.	3.5	25
169	Allogeneic Hematopoietic Cell Transplantation (HCT) after Nonmyeloablative Conditioning for Relapsed or Refractory Follicular Lymphoma.. Blood, 2005, 106, 1130-1130.	1.4	25
170	A Polymorphic Oncofetal Antigen Recognized by CD8+ CTL from Two Patients Experiencing Regression of Metastatic Renal Cell Carcinoma after Allogeneic HCT.. Blood, 2005, 106, 3097-3097.	1.4	25
171	HLA-Haploidentical Hematopoietic Cell Transplantation for Treatment of Nonmalignant Diseases Using Nonmyeloablative Conditioning and Post-Transplant Cyclophosphamide. Biology of Blood and Marrow Transplantation, 2020, 26, 1332-1341.	2.0	24
172	THE USE OF AN ANTI-TCR???? MONOCLONAL ANTIBODY TO CONTROL HOST-VERSUS-GRAFT REACTIONS IN CANINE MARROW ALLOGRAFT RECIPIENTS CONDITIONED WITH LOW DOSE TOTAL BODY IRRADIATION1. Transplantation, 1999, 67, 1329-1335.	1.0	24
173	Fludarabine and 2-Gy TBI is Superior to 2ÂGy TBI as Conditioning for HLA-Matched Related Hematopoietic Cell Transplantation: A Phase III Randomized Trial. Biology of Blood and Marrow Transplantation, 2013, 19, 1340-1347.	2.0	23
174	Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research. Haematologica, 2020, 105, 1329-1338.	3.5	23
175	Dog leukocyte antigen-haploidentical stem cell allografts after anti-CD44 therapy and reduced-intensity conditioning in a preclinical canine model. Experimental Hematology, 2003, 31, 168-175.	0.4	22
176	A Limited Sampling Schedule to Estimate Individual Pharmacokinetic Parameters of Fludarabine in Hematopoietic Cell Transplant Patients. Clinical Cancer Research, 2009, 15, 5280-5287.	7.0	22
177	Impact of pretransplant measurable residual disease on the outcome of allogeneic hematopoietic cell transplantation in adult monosomal karyotype AML. Leukemia, 2020, 34, 1577-1587.	7.2	22
178	Prevention of Graft-versus-Host Disease.. Annals of the New York Academy of Sciences, 1995, 770, 149-164.	3.8	21
179	Pharmacokinetic and Pharmacodynamic Analysis of Inosine Monophosphate Dehydrogenase Activity in Hematopoietic Cell Transplantation Recipients Treated with Mycophenolate Mofetil. Biology of Blood and Marrow Transplantation, 2014, 20, 1121-1129.	2.0	21
180	Yttrium-90-labeled anti-CD45 antibody followed by a reduced-intensity hematopoietic cell transplantation for patients with relapsed/refractory leukemia or myelodysplasia. Haematologica, 2020, 105, 1731-1737.	3.5	20

#	Article	IF	Citations
181	Mechanisms of Enhancement of Natural Killer Activity by an Antibody to CD44: Increase in Conjugate Formation and Release of Tumor Necrosis Factor Î±. Cellular Immunology, 1995, 164, 255-264.	3.0	19
182	Radioimmunotherapy as non-myeloablative conditioning for allogeneic marrow transplantation. Leukemia and Lymphoma, 2006, 47, 1205-1214.	1.3	19
183	Extended Mycophenolate Mofetil and Shortened Cyclosporine Failed to Reduce Graft-versus-Host Disease after Unrelated Hematopoietic Cell Transplantation with Nonmyeloablative Conditioning. Biology of Blood and Marrow Transplantation, 2007, 13, 1041-1048.	2.0	19
184	A novel phenotypic method to determine fludarabine triphosphate accumulation in T-lymphocytes from hematopoietic cell transplantation patients. Cancer Chemotherapy and Pharmacology, 2009, 63, 391-401.	2.3	19
185	Long-Term Outcomes of Patients with Persistent Indolent BÂCell Malignancies Undergoing Nonmyeloablative Allogeneic Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 281-287.	2.0	19
186	Prognostic Performance of the Augmented Hematopoietic Cell Transplantation-Specific Comorbidity/Age Index in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation from Alternative Graft Sources. Biology of Blood and Marrow Transplantation, 2019, 25, 1045-1052.	2.0	19
187	131I-Anti-CD45 Antibody Plus Fludarabine, Low-Dose Total Body Irradiation and Peripheral Blood Stem Cell Infusion for Elderly Patients with Advanced Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS).. Blood, 2005, 106, 397-397.	1.4	19
188	It Is Easix to Predict Non-Relapse Mortality (NRM) of Allogeneic Stem Cell Transplantation (alloSCT). Blood, 2016, 128, 519-519.	1.4	19
189	Î±-Imaging Confirmed Efficient Targeting of CD45-Positive Cells After ²¹¹At-Radioimmunotherapy for Hematopoietic Cell Transplantation. Journal of Nuclear Medicine, 2015, 56, 1766-1773.	5.0	18
190	Disability related to chronic graft -versus-host disease after alternative donor hematopoietic cell transplantation. Haematologica, 2019, 104, 835-843.	3.5	18
191	Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. Blood Advances, 2020, 4, 3180-3190.	5.2	18
192	Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: Improved outcomes over two decades. Haematologica, 2021, 106, 1599-1607.	3.5	18
193	Intensive Versus Non-Intensive Induction Therapy for Patients (Pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) Using Two Different Novel Prognostic Models. Blood, 2016, 128, 216-216.	1.4	18
194	Immunomodulatory effects induced by cytotoxic T lymphocyte antigen 4 immunoglobulin with donor peripheral blood mononuclear cell infusion in canine major histocompatibility complexâ€“haplo-identical non-myeloablative hematopoietic cell transplantation. Cytotherapy, 2011, 13, 1269-1280.	0.7	17
195	A Phase I/II Study of Chemotherapy Followed by Donor Lymphocyte Infusion plus Interleukin-2 for Relapsed Acute Leukemia after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2011, 17, 1308-1315.	2.0	17
196	A Limited Sampling Schedule to Estimate Mycophenolic Acid Area Under the Concentrationâ€Time Curve in Hematopoietic Cell Transplantation Recipients. Journal of Clinical Pharmacology, 2012, 52, 1654-1664.	2.0	17
197	Targeted Cancer Therapy Using Radiolabeled Monoclonal Antibodies. Technology in Cancer Research and Treatment, 2005, 4, 393-405.	1.9	16
198	211Astatine-Conjugated Monoclonal CD45 Antibody-Based Nonmyeloablative Conditioning for Stem Cell Gene Therapy. Human Gene Therapy, 2015, 26, 399-406.	2.7	16

#	Article	IF	Citations
199	Sirolimus with CSP and MMF as GVHD prophylaxis for allogeneic transplantation with HLA antigenâ€“mismatched donors. Blood, 2020, 136, 1499-1506.	1.4	16
200	Phase I Study of a CD45-Targeted Antibodyâ€“Radionuclide Conjugate for High-Risk Lymphoma. Clinical Cancer Research, 2019, 25, 6932-6938.	7.0	15
201	Comparative analysis of total body irradiation (TBI)-based and non-TBI-based myeloablative conditioning for acute myeloid leukemia in remission with or without measurable residual disease. Leukemia, 2020, 34, 1701-1705.	7.2	15
202	Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myelogenous Leukemia and Myelodysplastic Syndromes with Low/Intermediate but not High Disease Risk Index: A Center for International Blood and Marrow Transplant Research Study. Transplantation and Cellular Therapy, 2021, 27, 68.e1-68.e9.	1.2	15
203	Allogeneic Transplantation to Treat Therapy-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Adults. Transplantation and Cellular Therapy, 2021, 27, 923.e1-923.e12.	1.2	15
204	Low Albumin, High Ferritin, and Thrombocytopenia Before Transplant Predict Non-Relapse Mortality (NRM) Independent of the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI).. Blood, 2009, 114, 651-651.	1.4	15
205	Tandem autologous/allogeneic hematopoietic cell transplantation with bortezomib maintenance therapy for high-risk myeloma. Blood Advances, 2017, 1, 2247-2256.	5.2	15
206	Pilot Study of a 213Bismuth-Labeled Anti-CD45 mAb as a Novel Nonmyeloablative Conditioning for DLA-Haploidentical Littermate Hematopoietic Transplantation. Transplantation, 2010, 89, 1336-1340.	1.0	14
207	Association of fludarabine pharmacokinetic/dynamic biomarkers with donor chimerism in nonmyeloablative HCT recipients. Cancer Chemotherapy and Pharmacology, 2015, 76, 85-96.	2.3	14
208	Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for I nternational B lood and M arrow T ransplant R esearch cohort analysis. Cancer, 2017, 123, 2035-2042.	4.1	14
209	Allogeneic Hematopoietic Cell Transplantation in the Outpatient Setting. Biology of Blood and Marrow Transplantation, 2019, 25, 2152-2159.	2.0	14
210	Total body irradiation dose escalation decreases risk of progression and graft rejection after hematopoietic cell transplantation for myelodysplastic syndromes or myeloproliferative neoplasms. Haematologica, 2019, 104, 1221-1229.	3.5	14
211	Type of post-grafting immunosuppression after non-myeloablative blood cell transplantation may influence risk of delayed haemolysis due to minor abo incompatibility. British Journal of Haematology, 2002, 116, 500-501.	2.5	13
212	Reduced Toxicity and Prompt Engraftment After Minimal Conditioning of a Patient With Fanconi Anemia Undergoing Hematopoietic Stem Cell Transplantation From an HLA-Matched Unrelated Donor. Journal of Pediatric Hematology/Oncology, 2003, 25, 581-583.	0.6	13
213	Dog leukocyte antigen nonidentical unrelated canine marrow grafts: enhancement of engraftment by CD4 and CD8 T cells. Transplantation, 2003, 76, 474-480.	1.0	13
214	Population pharmacokinetic/dynamic model of lymphosuppression after fludarabine administration. Cancer Chemotherapy and Pharmacology, 2015, 75, 67-75.	2.3	13
215	Description and prognostic significance of the kinetics of minimal residual disease status in adults with acute lymphoblastic leukemia treated with HyperCVAD. American Journal of Hematology, 2018, 93, 546-552.	4.1	13
216	High prevalence of potential drug interactions affecting mycophenolic acid pharmacokinetics in nonmyeloablative hematopoietic stem cell transplant recipients. International Journal of Clinical Pharmacology and Therapeutics, 2013, 51, 711-7.	0.6	13

#	Article	IF	Citations
217	Comparison of characteristics and outcomes of late acute and NIH chronic GVHD between Japanese and white patients. Blood Advances, 2019, 3, 2764-2777.	5.2	12
218	Engraftment of DLA-haploidentical marrow with ex vivo expanded, retrovirally transduced cytotoxic T lymphocytes. Blood, 2001, 98, 3447-3455.	1.4	11
219	Delaying DLA-Haploidentical Hematopoietic Cell Transplantation after Total Body Irradiation. Biology of Blood and Marrow Transplantation, 2009, 15, 1244-1250.	2.0	11
220	Low-Dose Azacitidine with DNMT1 Level Monitoring to Treat Post-Transplantation Acute Myelogenous Leukemia or Myelodysplastic Syndrome Relapse. Biology of Blood and Marrow Transplantation, 2019, 25, 1122-1127.	2.0	10
221	Rituximab-based allogeneic transplant for chronic lymphocytic leukemia with comparison to historical experience. Bone Marrow Transplantation, 2020, 55, 172-181.	2.4	10
222	Nonmyeloablative and Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies: Outcomes with HLA-Matched Unrelated Donors Compared to HLA-Identical Sibling Donors.. Blood, 2005, 106, 658-658.	1.4	10
223	A Phase II Trial of 90Y-Ibritumomab Tiuxetan-Based Reduced Intensity Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation for Relapsed CD20+ B-Cell Non-Hodgkins Lymphoma (NHL).. Blood, 2006, 108, 316-316.	1.4	10
224	Failure of Donor Lymphocyte Infusion to Prevent Graft Rejection in Dogs Given DLA-Identical Marrow after 1 Gy of Total Body Irradiation. Biology of Blood and Marrow Transplantation, 2006, 12, 813-817.	2.0	9
225	Transmission and expansion of HOXB4-induced leukemia in two immunosuppressed dogs: Implications for a new canine leukemia model. Experimental Hematology, 2009, 37, 1157-1166.	0.4	9
226	A pilot pharmacologic biomarker study in HLA-haploidentical hematopoietic cell transplant recipients. Cancer Chemotherapy and Pharmacology, 2013, 72, 607-618.	2.3	9
227	Preâ€transplant comorbidity burden and postâ€transplant chronic graftâ€versusâ€host disease. British Journal of Haematology, 2015, 171, 411-416.	2.5	9
228	Inosine Monophosphate Dehydrogenase Pharmacogenetics in Hematopoietic Cell Transplantation Patients. Biology of Blood and Marrow Transplantation, 2018, 24, 1802-1807.	2.0	9
229	Long-Term Follow-Up of 90Y-Ibritumomab Tiuxetan, Fludarabine, and Total Body Irradiationâ€“Based Nonmyeloablative Allogeneic Transplant Conditioning for Persistent High-Risk B Cell Lymphoma. Biology of Blood and Marrow Transplantation, 2018, 24, 2211-2215.	2.0	9
230	Favorable Outcome of Patients with Relapsed Hodgkin Lymphoma (HL) after Nonmyeloablative Hematopoietic Cell Transplantation (NM-HCT) Using Related Haploidentical Donors.. Blood, 2006, 108, 3135-3135.	1.4	9
231	Vaccination as a treatment for breast or ovarian cancer. Expert Review of Vaccines, 2004, 3, 269-277.	4.4	8
232	Allogeneic hematopoietic cell transplantation for renal cell carcinoma: ten years after. Expert Opinion on Biological Therapy, 2011, 11, 763-773.	3.1	8
233	Safety of treatment with DLA-identical or unrelated mesenchymal stromal cells in DLA-identical canine bone marrow transplantation. Chimerism, 2013, 4, 95-101.	0.7	8
234	Characterization of an Anti-Cd44 Single-Chain F_VAntibody That Stimulates Natural Killer Cell Activity and Induces TNFÎ± Release. Immunological Investigations, 1995, 24, 907-926.	2.0	7

#	Article	IF	Citations
235	Antibody engagement of intercellular adhesion molecule 3 triggers apoptosis of normal and leukaemic myeloid marrow cells. British Journal of Haematology, 2000, 108, 157-166.	2.5	7
236	Prolonged Allogeneic Marrow Engraftment following Nonmyeloablative Conditioning Using 100 cGy Total Body Irradiation and Pentostatin before and Pharmacological Immunosuppression after Transplantation. Transplantation, 2005, 80, 1518-1521.	1.0	7
237	Intracellular disposition of fludarabine triphosphate in human natural killer cells. Cancer Chemotherapy and Pharmacology, 2009, 63, 959-964.	2.3	7
238	Plerixafor-moblized stem cells alone are capable of inducing early engraftment across the MHC-haploidentical canine barrier. Blood, 2010, 115, 916-917.	1.4	7
239	Allogeneic hematopoietic cell transplantation for indolent non-Hodgkin lymphoma. Current Opinion in Hematology, 2013, 20, 509-514.	2.5	7
240	Costs of Second Allogeneic Hematopoietic Cell Transplantation. Transplantation, 2013, 96, 108-115.	1.0	7
241	Recipient Pretransplant Inosine Monophosphate Dehydrogenase Activity in Nonmyeloablative Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 1544-1552.	2.0	7
242	Pretransplant Consolidation Is Not Beneficial for Adults with ALL Undergoing Myeloablative Allogeneic Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 945-955.	2.0	7
243	Therapy of Myeloid Leukemia using Novel Bispecific Fusion Proteins Targeting CD45 and 90Y-DOTA. Molecular Cancer Therapeutics, 2020, 19, 2575-2584.	4.1	7
244	Yttrium-90 Anti-CD45 Immunotherapy Followed by Autologous Hematopoietic Cell Transplantation for Relapsed or Refractory Lymphoma. Transplantation and Cellular Therapy, 2021, 27, 57.e1-57.e8.	1.2	7
245	Outcomes among Patients with Recurrent High-Risk Hematologic Malignancy after Nonmyeloablative Versus Myeloablative Allogeneic Hematopoietic Cell Transplantation.. Blood, 2006, 108, 262-262.	1.4	7
246	Allogeneic hematopoietic cell transplant for patients with end stage renal disease requiring dialysis â€“ a single institution experience. Leukemia and Lymphoma, 2017, 58, 740-742.	1.3	6
247	Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter Trial. Biology of Blood and Marrow Transplantation, 2018, 24, 308-313.	2.0	6
248	90Y-labeled anti-CD45 antibody allogeneic hematopoietic cell transplantation for high-risk multiple myeloma. Bone Marrow Transplantation, 2021, 56, 202-209.	2.4	6
249	Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 2021, 56, 2108-2117.	2.4	6
250	Safety and Efficacy of Yttrium-90-Labeled Anti-CD45 Antibody (90Y-DOTA-BC8) Followed By a Standard Reduced-Intensity Hematopoietic Stem Cell Transplant (HCT) Regimen for Patients with Refractory/Relapsed Leukemia or High-Risk Myelodysplastic Syndrome (MDS). Blood, 2018, 132, 1018-1018.	1.4	6
251	Superiority of Pediatric Chemotherapy over Allogeneic Hematopoietic Cell Transplantation for Philadelphia Chromosome Negative Adult ALL in First Complete Remission: A Combined Analysis of Dana-Farber ALL Consortium and CIBMTR Cohorts. Blood, 2014, 124, 319-319.	1.4	6
252	Development of [211At]astatine-based anti-CD123 radioimmunotherapy for acute leukemias and other CD123+ malignancies. Leukemia, 2022, 36, 1485-1491.	7.2	6

#	Article	IF	Citations
253	FAILURE OF ANTI-Ia MONOCLONAL ANTIBODY TO ABROGATE TRANSFUSION-INDUCED SENSITIZATION AND PREVENT MARROW GRAFT REJECTION IN DLA-IDENTICAL CANINE LITTERMATES. Transplantation, 1988, 45, 505.	1.0	5
254	Phase I/II multisite trial of optimally dosed clofarabine and lowâ€dose TBI for hematopoietic cell transplantation in acute myeloid leukemia. American Journal of Hematology, 2020, 95, 48-56.	4.1	5
255	Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML. Blood Advances, 2022, 6, 828-847.	5.2	5
256	Reduced-intensity Conditioning Followed by Hematopoietic Cell Transplantation for Hematologic Malignancies. , 0, , 1043-1058.		5
257	Superior Survival with Post-Remission Pediatric-Inspired Chemotherapy Compared to Myeloablative Allogeneic Hematopoietic Cell Transplantation in Adolescents and Young Adults with Ph-Negative Acute Lymphoblastic Leukemia in First Complete Remission: Comparison of CALGB 10403 to Patients Reported to the CIBMTR. Blood, 2019, 134, 261-261.	1.4	5
258	Comparison of Allogeneic Hematopoietic Cell Transplantation (HCT) after Nonmyeloablative Conditioning with HLA-Matched Related (MRD), Unrelated (URD), and Related Haploidentical (Haplo) Donors for Relapsed or Refractory Hodgkin Lymphoma (HL).. Blood, 2007, 110, 173-173.	1.4	5
259	International Working Group Scores Predict Post-Transplant Outcomes In Patients with Myelofibrosis. Blood, 2010, 116, 3085-3085.	1.4	5
260	A Phase I Trial of 90Y-BC8-DOTA (Anti-CD45) Monoclonal Antibody in Combination with Fludarabine and TBI As Conditioning for Allogeneic Peripheral Blood Stem Cell Transplant to Treat High Risk Multiple Myeloma. Blood, 2017, 130, 910-910.	1.4	5
261	Sequential Autologous Followed by Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT) From HLA-Matched Related or Unrelated Donors Improves Outcomes of Patients (pts) with Bulky Lymphoma or Chronic Lymphocytic Leukemia (CLL). Blood, 2010, 116, 2365-2365.	1.4	5
262	Impact of Rituximab and Host/Donor Fc Receptor Polymorphisms after Allogeneic Hematopoietic Cell Transplantation for CD20+ B Cell Malignancies. Biology of Blood and Marrow Transplantation, 2020, 26, 1811-1818.	2.0	4
263	Biokinetics of Radiolabeled Monoclonal Antibody BC8: Differences in Biodistribution and Dosimetry Among Hematologic Malignancies. Journal of Nuclear Medicine, 2020, 61, 1300-1306.	5.0	4
264	Addition of Astatine-211-Labeled Anti-CD45 Antibody to TBI as Conditioning for DLA-Identical Marrow Transplantation: A Novel Strategy to Overcome Graft Rejection in a Canine Presensitization Model: â€œRadioimmunotherapy to Overcome Transfusion-Induced Sensitizationâ€• Transplantation and Cellular Therapy, 2021, 27, 476.e1-476.e7.	1.2	4
265	Conversion of Low Donor Chimerism Following Nonmyeloablative Conditioning for Hematopoietic Cell Transplantation (HCT) Using Pentostatin and Donor Lymphocyte Infusion (DLI).. Blood, 2004, 104, 186-186.	1.4	4
266	Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT) for Refractory Waldenstromâ€™s Macroglobulinemia (WM): Evidence for a Graft-Versus-WM Effect.. Blood, 2006, 108, 3034-3034.	1.4	4
267	Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Patients with De Novo and Secondary Acute Myeloid Leukemia. Blood, 2008, 112, 149-149.	1.4	4
268	Sustained Graft-Versus-Lymphoma Effect among Patients (pts) with Mantle Cell Lymphoma (MCL) Given Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT).. Blood, 2008, 112, 2147-2147.	1.4	4
269	A Randomized 3-Arm Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute Graft-Versus-Host Disease (GVHD) After Unrelated Donor Hematopoietic Cell Transplantation (HCT) Using Nonmyeloablative Conditioning for Patients with Hematologic Malignancies: A Multi-Center Trial.. Blood, 2009, 114, 348-348.	1.4	4
270	Multi-Institutional Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) for HCT Outcomes. Blood, 2011, 118, 145-145.	1.4	4

#	Article	IF	Citations
271	FLT3 Mutation Increases Relapse Risk after Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia in First or Second Complete Remission: A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis. Blood, 2014, 124, 322-322.	1.4	4
272	Nonmyeloablative Conditioning and Hematopoietic Cell Transplantation (HCT) from HLA-Matched Related or Unrelated Donors for Chemotherapy-Refractory Chronic Lymphocytic Leukemia (CLL).. Blood, 2004, 104, 2323-2323.	1.4	4
273	An anti-CD44 antibody does not enhance engraftment of DLA-identical marrow after low-dose total body irradiation. Transplant Immunology, 1996, 4, 271-274.	1.2	3
274	Optimizing reduced-intensity conditioning regimens for myeloproliferative neoplasms. Expert Review of Hematology, 2010, 3, 23-33.	2.2	3
275	Conditioning with Î±-emitter based radioimmunotherapy in canine allogeneic hematopoietic cell transplantation. Chimerism, 2012, 3, 40-42.	0.7	3
276	Effect of allogeneic hematopoietic cell transplantation in first complete remission on post-relapse complete remission rate and survival in acute myeloid leukemia. Haematologica, 2015, 100, e254-e256.	3.5	3
277	Blood and marrow transplantation during the emerging COVID-19 pandemic: the Seattle approach. Bone Marrow Transplantation, 2021, 56, 305-313.	2.4	3
278	Effect of post-treatment MRD status on subsequent outcomes according to chemotherapy intensity in acute myeloid leukemia (AML). Leukemia and Lymphoma, 2021, 62, 1532-1535.	1.3	3
279	Hematopoietic Bone Marrow Transplantation (BMT) for Patients with High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) Using HLA-Haploidentical Related Donors: A Trial Using Radiolabeled Anti-CD45 Antibody Combined with Immunosuppression Before and After BMT. Blood, 2012, 120, 4164-4164.	1.4	3
280	Role of Comorbidities in Prognostic Evaluation of Outcomes Following Allogeneic Hematopoietic Cell Transplantation (HCT) from HLA-Mismatched (MM) and Umbilical Cord Blood (UCB) Donor Grafts. Blood, 2014, 124, 2583-2583.	1.4	3
281	Prophylactic Natural Killer Cell Immunotherapy Following HLA-Haploidentical Hematopoietic Cell Transplantation Prevents Relapse and Improves Survival in Patients with High-Risk Hematological Malignancies. Blood, 2016, 128, 1161-1161.	1.4	3
282	Sirolimus Combined with Mycophenolate Mofetil (MMF) and Cyclosporine (CSP) Significantly Improves Prevention of Acute Graft-Versus-Host-Disease (GVHD) after Unrelated Hematopoietic Cell Transplantation (HCT): Results from a Phase III Randomized Multi-Center Trial. Blood, 2016, 128, 506-506.	1.4	3
283	Comparison of Total Body Irradiation-Based with Intravenous Busulfan-Based Chemotherapy-Only Conditioning Regimens for Myeloablative Hematopoietic Cell Transplantation (HCT) in Adults with Acute Lymphoblastic Leukemia. Blood, 2016, 128, 679-679.	1.4	3
284	Megadose 90Y-ibritumomab tiuxetan prior to allogeneic transplantation is effective for aggressive large B-cell lymphoma. Blood Advances, 2022, 6, 37-45.	5.2	3
285	A Modified Hematopoietic Cell Transplantation (HCT)-Specific-Comorbidity Index.. Blood, 2004, 104, 1146-1146.	1.4	3
286	Umbilical Cord Blood Transplantation in Patients with Hematological Malignancies Using a Non-ATG Containing Reduced Intensity Preparative Regimen. Blood, 2011, 118, 1943-1943.	1.4	3
287	Outcomes after hematopoietic cell transplantation among non-English- compared to English-speaking recipients. Bone Marrow Transplantation, 2022, 57, 440-444.	2.4	3
288	Nonmyeloablative hematopoietic stem cell allografting. Current Opinion in Organ Transplantation, 2000, 5, 366-371.	1.6	2

#	Article	IF	Citations
289	Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant in Patients with End Stage Renal Disease Requiring Dialysis â€“ a Single Institution Experience. Biology of Blood and Marrow Transplantation, 2014, 20, S251.	2.0	2
290	Allogeneic Hematopoietic Cell Transplantation (HCT) in the Eighth Decade of Life: How Much Does Age Matter?. Biology of Blood and Marrow Transplantation, 2017, 23, S98-S99.	2.0	2
291	Non-myeloablative allogeneic hematopoietic cell transplantation for relapsed or refractory WaldenstrÃ¶m macroglobulinemia: evidence for a graft- versus -lymphoma effect. Haematologica, 2018, 103, e252-e255.	3.5	2
292	Survival Differences Among Patients (pts) with Acute Myeloid Leukemia (AML) Treated with Allogeneic Hematopoietic Cell Transplantation (HCT) Versus Non-HCT Therapies: A Large Real-Time Multi-Center Prospective Longitudinal Observational Study. Blood, 2018, 132, 207-207.	1.4	2
293	The Alpha Emitter Astatine-211 Targeted to CD38 Can Eradicate Multiple Myeloma in Minimal Residual Disease Models. Blood, 2018, 132, 1941-1941.	1.4	2
294	Nonmyeloablative Unrelated Donor Hematopoietic Cell Transplantation (HCT) for Patients (pts) with Poor Risk, Relapsed or Refractory Multiple Myeloma.. Blood, 2004, 104, 2756-2756.	1.4	2
295	Treatment for Acute Myelogenous Leukemia by Low Dose Irradiation Based Conditioning and Hematopoietic Cell Transplantation from Related and Unrelated Donors.. Blood, 2004, 104, 3074-3074.	1.4	2
296	Relationship between Conditioning Intensity and Comorbidity in Patients (Pts) with Acute Myeloid Leukemia (AML) or Myelodysplasia (MDS) Receiving Allogeneic Hematopoietic Cell Transplantation (HCT).. Blood, 2005, 106, 705-705.	1.4	2
297	What Is the Role for Donor NK Cells after Nonmyeloablative Conditioning?. Blood, 2007, 110, 476-476.	1.4	2
298	Allogeneic Hematopoietic Cell Transplantation (HCT) after Nonmyeloablative Conditioning for Patients (pts) Aged â‰¥60 Years.. Blood, 2008, 112, 2162-2162.	1.4	2
299	Impacts of Cytogenetic Abnormalities and Prior Alemtuzumab on Outcomes of Patients (pts) with High-Risk Chronic Lymphocytic Leukemia (CLL) Given Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT). Blood, 2010, 116, 2364-2364.	1.4	2
300	Effect of Peripheral Blood Stem Cell (PBSC) Graft Composition on Graft Versus Host Disease (GVHD) and Mortality After Allogeneic Transplantation. Blood, 2010, 116, 676-676.	1.4	2
301	Interaction of Age and Comorbidities and Their Impacts on Hematopoietic Cell Transplantation (HCT) Outcomes. Blood, 2011, 118, 665-665.	1.4	2
302	Comparison of Post-Allogeneic Hematopoietic Cell Transplantation (HCT) Outcomes after Matched Related Donor Versus Matched Unrelated Donor HCT in Adults with Acute Lymphoblastic Leukemia. Blood, 2015, 126, 2017-2017.	1.4	2
303	Analysis of Pre-Transplant Therapy with Brentuximab Vedotin for Relapsed/Refractory Hodgkin Lymphoma on Outcomes of Reduced Intensity Conditioned Allogeneic Hematopoietic Cell Transplantation. Blood, 2015, 126, 4406-4406.	1.4	2
304	Higher Doses of Transplanted T and B Cells Are Associated with Greater Incidence of Extensive Chronic GVHD after PBSC Transplantation from HLA-Identical Sibling Donors.. Blood, 2007, 110, 1077-1077.	1.4	2
305	Long-Term Outcome of Autologous Followed by Nonmyeloablative Allografting from HLA-Identical Sibling for Multiple Myeloma (MM).. Blood, 2007, 110, 3029-3029.	1.4	2
306	Treatment of Recurrent or Persistent AML/MDS After Allogeneic Hematopoietic Cell Transplantation with Azacitidine.. Blood, 2010, 116, 1288-1288.	1.4	2

#	Article	IF	Citations
307	Utility of theÂTreatment-Related Mortality (TRM)Âscore to predict outcomes of adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation. Leukemia, 2022, 36, 1563-1574.	7.2	2
308	CD8+ ACTIVATED T LYMPHOCYTES PRODUCE AN IN VITRO SKIN GRAFT-VERSUS-HOST REACTION IN AN ORGANOTYPIC SKIN CULTURE MODEL. Transplantation, 1995, 59, 69-78.	1.0	1
309	Pre-transplant bone marrow monocytic myeloid-derived suppressor cell frequency is not associated with outcome after allogeneic hematopoietic cell transplantation for acute myeloid leukemia in remission. Bone Marrow Transplantation, 2019, 54, 1511-1514.	2.4	1
310	Impact of Depth of Pretransplant Clinical Response on Outcomes of Acute Myeloid Leukemia Patients in First Complete Remission (AML-CR1) Who Undergo Allogeneic Hematopoietic Cell Transplantation (AlloHCT). Blood, 2019, 134, 4585-4585.	1.4	1
311	Non-Ablative or Reduced Intensity Conditioning Regimens with Volunteer Unrelated Donor Progenitor Cell Transplantation.. Blood, 2004, 104, 2751-2751.	1.4	1
312	Higher Doses of Transplanted CD34+, CD3+ and CD8+ Cells Are Associated with Better Donor T-Cell Chimerism and Less Graft Rejection, but Not with GVHD after Nonmyeloablative Conditioning for Unrelated Hematopoietic Cell Transplantation.. Blood, 2004, 104, 2753-2753.	1.4	1
313	Platelet and Red Blood Cell (RBC) Transfusion Requirements of Nonmyeloablative (NM) HLA-Matched Related and Unrelated Donor Hematopoietic Cell Transplantation (HCT): Influence of Genetic Disparity and ABO-Incompatibility.. Blood, 2006, 108, 2985-2985.	1.4	1
314	Allogeneic Hematopoietic Cell Transplants in Patients with Myelofibrosis Age 60 and Older. Blood, 2008, 112, 2798-2798.	1.4	1
315	A Relapse Risk Score to Predict Acute Myeloid Leukemia Relapse After Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation Based on Pre-Transplant Variables.. Blood, 2010, 116, 3450-3450.	1.4	1
316	Second Allogeneic Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies for Relapse After First Allografts. Blood, 2012, 120, 4207-4207.	1.4	1
317	Non-Myeloablative Allografting from HLA-Identical Sibling Donors for Treatment of CML.. Blood, 2004, 104, 2316-2316.	1.4	1
318	Relapse Risk after Nonmyeloablative Hematopoietic Cell Transplantation for Malignant Diseases.. Blood, 2005, 106, 703-703.	1.4	1
319	Nonmyeloablative Unrelated Donor (URD) Hematopoietic Cell Transplantation (HCT) for the Treatment of Patients (pts) with Poor-Risk, Relapsed or Refractory Multiple Myeloma.. Blood, 2005, 106, 2893-2893.	1.4	1
320	Outcomes of c Hematopoietic Stem Cell Transplantation (HCT) after Non-Myeloablative Conditioning in Relapsed, Refractory, or Transformed Indolent Non-Hodgkin Lymphoma (NHL).. Blood, 2006, 108, 3124-3124.	1.4	1
321	The Joint Role of Comorbidity and Performance Status (PS) in Predicting Morbidity after Allogeneic Nonmyeloablative Hematopoietic Cell Transplantation (HCT).. Blood, 2006, 108, 596-596.	1.4	1
322	Long-Term Follow Up of Patients (pts) with High-Risk Chronic Lymphocytic Leukemia (CLL) Given Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT).. Blood, 2007, 110, 1662-1662.	1.4	1
323	Outcomes of Early Relapse Following Non-Myeloablative Allogeneic Transplant for Lymphoma.. Blood, 2009, 114, 1204-1204.	1.4	1
324	Falling Serum Albumin Predicts Severity of Acute Graft-Vs.-Host Disease and Non-Relapse Mortality After Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation.. Blood, 2009, 114, 1146-1146.	1.4	1

#	Article	IF	Citations
325	Impact of Comorbidities on Early and Late Mortalities After Allogeneic Hematopoietic Cell Transplantation (HCT). Blood, 2011, 118, 326-326.	1.4	1
326	Pre-Transplant Ferritin, Albumin and Platelet Count Add Prognostic Information to Comorbidities for Allogeneic Hematopoietic Cell Transplantation (HCT) Outcomes: A Multi-Center Discovery-Validation Study. Blood, 2014, 124, 421-421.	1.4	1
327	A Prospective Multicenter Study of Nonmyeloablative Conditioning with TBI or Fludarabine/TBI for HLA-Matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies with Post Grafting Immunosuppression with Tacrolimus and Mycophenolate Mofetil: 10-Year Experience. Blood, 2015, 126, 1949-1949.	1.4	1
328	A Novel Bispecific CD38 Antibody Eradicates Multiple Myeloma in a Mouse Model Following Yttrium-90-DOTA Capture. Blood, 2015, 126, 118-118.	1.4	1
329	Addition of Astatine-211-Labeled Anti-CD45 Antibody to Total Body Irradiation (TBI) As Conditioning for DLA-Identical Marrow Transplantation: A Novel Strategy to Overcome Graft Rejection in a Canine Presensitization Model. Blood, 2016, 128, 2152-2152.	1.4	1
330	Comparison of Chronic Graft-Versus-Host Disease Severity and Functional Status after Cord Blood, Haploidentical Related and 1-Allele Mismatched Unrelated Donor Hematopoietic Cell Transplantation. Blood, 2017, 130, 73-73.	1.4	1
331	Total Body Irradiation (TBI) Dose Escalation Decreases Risk of Progression and Graft Rejection after Hematopoietic Cell Transplantation with Nonmyeloablative Conditioning for Myelodysplastic Syndrome (MDS) or Myeloproliferative Neoplasms (MPN). Blood, 2017, 130, 908-908.	1.4	1
332	Allogeneic Hematopoietic Stem Cell Transplantation for Therapy-Related Myelodysplastic Syndromes and Acute Myeloid Leukemia. Blood, 2019, 134, 2036-2036.	1.4	1
333	Anti-tumor activity of an ICAM-3 antibody (ICM3) Against human leukemic xenograft tumors in nude mice. Experimental Hematology, 2000, 28, 59-60.	0.4	0
334	Radioimmunotherapy-Augmented Nonmyeloablative Allogeneic Transplantation Improves Outcomes for Refractory Indolent B-Cell Non-Hodgkin Lymphoma: Results of an Adjusted Cohort Analysis. Biology of Blood and Marrow Transplantation, 2014, 20, S72-S73.	2.0	0
335	Long-Term Outcomes of Patients with Advanced Mantle Cell Lymphoma Treated with Allogeneic Hematopoietic Cell Transplantation after Nonmyeloablative Conditioning. Biology of Blood and Marrow Transplantation, 2015, 21, S88-S89.	2.0	0
336	Allogeneic Hematopoietic Cell Transplantation (HCT) Yields Lower Relapse Rates but No Overall Survival Benefit for Adults with Acute Lymphoblastic Leukemia (ALL) in First Minimal Residual Disease (MRD)-Negative Remission. Biology of Blood and Marrow Transplantation, 2015, 21, S80-S81.	2.0	0
337	Consistent Collection and Processing of Non-Mobilized Mononuclear Cell, Apheresis Products from HLA Haploidentical Bone Marrow Donors for Sequential CD3+ T-Cell Depletion and CD56+ NK Cell Enrichment. Biology of Blood and Marrow Transplantation, 2016, 22, S382-S383.	2.0	0
338	Late Effects and Patient Reported Quality of Life by Donor Source at 3 Years in Patients Surviving at Least 1 Year Following Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, S29.	2.0	0
339	HLA-Matched Sibling Versus Haploidentical Hematopoietic Cell Transplantation (HCT) in Patients with Acute Myeloid Leukemia (AML) in First Complete Remission (CR1). Biology of Blood and Marrow Transplantation, 2019, 25, S59-S60.	2.0	0
340	Limitations to Receiving Allogeneic Hematopoietic Cell Transplantation for Treatment of Acute Myeloid Leukemia: A Large Multi-Center Prospective Longitudinal Observational Study. Biology of Blood and Marrow Transplantation, 2019, 25, S115-S116.	2.0	0
341	Impact of Peri-Transplant Rituximab and Host/Donor Fc Receptor Polymorphisms for Patients with Relapsed or Refractory CD20+ B-Cell Malignancies. Biology of Blood and Marrow Transplantation, 2020, 26, S226-S227.	2.0	0
342	AML-145: Multicenter 11-Year Experience of Outcomes After Intensive Versus Less-Intensive Therapy for Patients with Acute Myeloid Leukemia: Focus on Older and Medically Infirm Patients. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, S185.	0.4	0

#	Article	IF	Citations
343	MLL-Rearranged AML Is Associated with Poor Outcomes As Compared to Patients with Intermediate- and Adverse-Risk Disease: A CIBMTR Study of 3779 Adult Patients. Biology of Blood and Marrow Transplantation, 2020, 26, S10-S11.	2.0	0
344	Long-term Outcomes with Nonmyeloablative HLA-Identical Related Hematopoietic Cell Transplantation Using Tacrolimus and Mycophenolate Mofetil for Graft-versus-Host Disease Prophylaxis. Transplantation and Cellular Therapy, 2021, 27, 163.e1-163.e7.	1.2	0
345	Myeloablative Versus Nonmyeloablative Hemopoietic Cell Transplantation (HCT) for Patients with Myelodysplasia (MDS) or AML with Multilineage Dysplasia Following MDS (tAML).. Blood, 2004, 104, 2320-2320.	1.4	0
346	Prognostic Relevance of â€œEarly-Onsetâ€•Graft-Versus-Host Disease Following Nonmyeloablative Hematopoietic Cell Transplantation.. Blood, 2004, 104, 423-423.	1.4	0
347	Comparison of Lung Function after Nonmyeloablative Versus Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation.. Blood, 2004, 104, 5105-5105.	1.4	0
348	DLA-Haploidentical Stem Cell Allografts after Anti-CD44 Therapy and Nonmyeloablative Conditioning: The Impact of Donor Lymphocyte Infusion (DLI), Pentostatin and Graft Composition on Donor Chimerism and Rejection.. Blood, 2005, 106, 2194-2194.	1.4	0
349	Impacts of Comorbidities on Outcomes of Patients (pts) Diagnosed with B-Cell Malignancies and Treated with Allogeneic Hematopoietic Cell Transplantation (HCT) Using Nonmyeloablative (NM) vs Myeloablative (M) Conditioning.. Blood, 2006, 108, 550-550.	1.4	0
350	Serious Acute or Chronic Graft-Versus-Host Disease after Hematopoietic Cell Transplantation: A Comparison of Myeloablative and Non-Myeloablative Conditioning Regimens.. Blood, 2006, 108, 755-755.	1.4	0
351	High-Dose Methotrexate (MTX) as Part of a Novel Immunosuppressive Regimen in Canine MHC-Haploidentical Hematopoietic Cell Transplantation (HCT).. Blood, 2006, 108, 3180-3180.	1.4	0
352	Postgrafting Immunosuppression with Prolonged Mycophenolate Mofetil (MMF) and Truncated Cyclosporine (CSP) Failed To Reduce the Incidence of Graft-Versus-Host Disease (GVHD) after Unrelated Donor Hematopoietic Cell Transplantation (HCT) with Nonmyeloablative Conditioning.. Blood, 2006, 108, 3119-3119.	1.4	0
353	Reversal of Low Chimerism Following Nonmyeloablative (NM) Hematopoietic Cell Transplantation (HCT) Using Pentostatin and Donor Lymphocyte Infusions (DLI).. Blood, 2007, 110, 480-480.	1.4	0
354	Outcomes in the Recent Seattle Cord Blood Experience: Low TRM and Relapse; High Mild Acute GVHD and CMV Reactivation.. Blood, 2007, 110, 2019-2019.	1.4	0
355	Outcomes of Allogeneic Hematopoietic Cell Transplantation (HCT) after Non-Myeloablative Conditioning in Relapsed Diffuse Large B-Cell Lymphoma (DLBCL).. Blood, 2007, 110, 3037-3037.	1.4	0
356	Duration of Immunosuppressive Therapy for Chronic Graft-vs.-Host Disease (cGVHD) Following Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation (HCT).. Blood, 2007, 110, 1071-1071.	1.4	0
357	A Large Cohort Analysis of CMV Viral Load and Ganciclovir-Related Neutropenia in Nonmyeloablative (NM-HCT) and Myeloablative (M-HCT) Allogeneic Hematopoietic Cell Transplant Recipients.. Blood, 2007, 110, 2975-2975.	1.4	0
358	Low-Dose Total Body Irradiation (TBI) and Fludarabine Conditioning for Hematopoietic Cell Transplantation (HCT) in Patients with HLA-Class I Mismatched Donors.. Blood, 2007, 110, 3067-3067.	1.4	0
359	Tandem Auto/AlloHCT for Newly Diagnosed Multiple Myeloma (MM) Patients.. Blood, 2008, 112, 1130-1130.	1.4	0
360	Transfusion Requirements in Allogeneic Hematopoietic Cell Transplantation (HCT) Recipients Given Either Myeloablative or Nonmyeloablative Conditioning, and Effect of ABO Incompatibility on HCT Outcomes.. Blood, 2008, 112, 3268-3268.	1.4	0

#	Article	IF	Citations
361	Evaluation of Toxicity and Tissue Radiation Doses Obtained in Mice with An Anti-CD45 Monoclonal Antibody (mAb) Labeled with the Alpha-Emitting Radionuclides, Astatine-211 or Bismuth-213.. Blood, 2008, 112, 3270-3270.	1.4	0
362	Adult Cord Blood Transplantation (CBT) Vs. Unrelated Donor Transplantation: A Cost Comparison. Blood, 2008, 112, 2383-2383.	1.4	0
363	Salvage Allogeneic Hematopoietic Cell Transplantation with Fludarabine and Total Body Irradiation (3) Tj ETQq1 1 0.784314 rgBT /Overlo	1.4	0
364	Reduced Intensity Conditioning with Allogeneic Hematopoietic Cell Transplantation for the Treatment of High-Risk Acute Lymphoblastic Leukemia.. Blood, 2009, 114, 1210-1210.	1.4	0
365	Nonmyeloablative Allogeneic HCT From Unrelated Donors for Multiple Myeloma (MM).. Blood, 2009, 114, 3391-3391.	1.4	0
366	Frequency of Allogeneic Stem Cell Transplant(SCT) in Patients Presenting with Newly-Diagnosed AML or AML at Time of First Salvage Therapy.. Blood, 2009, 114, 4332-4332.	1.4	0
367	Thymic Recovery After Allogeneic Hematopoietic Cell Transplantation with Nonmyeloablative Conditioning Might Be Limited to Patients Younger Than 60 Years of Age.. Blood, 2009, 114, 1149-1149.	1.4	0
368	Donor Engraftment Following Î±-Emitter Astatine-211 (211At) Labeled Anti-CD45 Monoclonal Antibody (mAb) Nonmyeloablative Conditioning for Dog Leukocyte Antigen (DLA)-Identical Marrow Transplantation. Blood, 2010, 116, 76-76.	1.4	0
369	Outcomes Following Relapse of Non-Hodgkin Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL) After Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation (HCT) From HLA-Matched Related or Unrelated Donors. Blood, 2010, 116, 1292-1292.	1.4	0
370	Concordance of CNS Leukemia Detection Between Morphology and Flow Cytometry Prior to Stem Cell Transplantation In Patients with MDS, AML, ALL and CMML. Blood, 2010, 116, 4842-4842.	1.4	0
371	Peripheral Blood Stem Cell Mobilization with Single Agent Plerixafor Induces FoxP3 Expression in Donor T Cells and Enables Durable Long Term Hematopoietic Engraftment Across Mismatched Major Histocompatibility Complex Barriers. Blood, 2011, 118, 1891-1891.	1.4	0
372	Incidence, Risk Factors and Outcomes of Sclerotic Chronic Graft-Versus-Host Disease (GVHD) Phenotype After Allogeneic Hematopoietic Cell Transplantation. Blood, 2011, 118, 322-322.	1.4	0
373	Quantitative Significance of Minimal Residual Disease Before Myeloablative Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in First and Second Complete Remission. Blood, 2012, 120, 655-655.	1.4	0
374	A Phase II Trial Combining Radiolabeled Anti-CD45 Antibody with Fludarabine and Low-Dose Total Body Irradiation (TBI) Followed by Related or Unrelated Hematopoietic Cell Transplantation for Patients Under Age 50 with Advanced Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS). Blood, 2012, 120, 1924-1924.	1.4	0
375	Donor Lymphocyte Infusion for Relapsed Hematological Malignancies After Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial CD3+ T Cell Dose. Blood, 2012, 120, 354-354.	1.4	0
376	Anti-CD45 Monoclonal Antibody (MAb) Dose Optimization For Astatine-211 (211At)-Radioimmunotherapy (RIT) Of Relapsed Non-Hodgkin Lymphoma (NHL) In a Canine Model. Blood, 2013, 122, 5139-5139.	1.4	0
377	The Effect Of Donor and Recipient Statin Treatment On Infections After Allogeneic Hematopoietic Cell Transplantation. Blood, 2013, 122, 4548-4548.	1.4	0
378	Modulated Cyclophosphamide-Based In Vivo T-Cell Depletion Promotes Engraftment With Minimal Gvhd and Low Toxicity In Fanconi Anemia Patients. Blood, 2013, 122, 4561-4561.	1.4	0

#	Article	IF	Citations
379	Failure-Free Survival After Initial Systemic Treatment Of Chronic GVHD. Blood, 2013, 122, 2053-2053.	1.4	0
380	Comparison Of Minimal Residual Disease As Outcome Predictor For AML Patients In First Complete Remission Undergoing Myeloablative Or Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation. Blood, 2013, 122, 1317-1317.	1.4	0
381	Effect of Allogeneic Hematopoietic Cell Transplant in First Complete Remission on Post-Relapse CR Rate and Survival in Acute Myeloid Leukemia. Blood, 2014, 124, 5257-5257.	1.4	0
382	211At-Anti-CD45 Radioimmunotherapy Can Replace TBI Prior to Haploidentical Bone Marrow Transplantation and Yield Long-Term Hematopoietic Engraftment. Blood, 2014, 124, 2417-2417.	1.4	0
383	Time to Minimal Residual Disease (MRD) Negativity Is Independently Predictive of Outcome in Adults with Acute Lymphoblastic Leukemia (ALL) Receiving Hyper-CVAD. Blood, 2015, 126, 2498-2498.	1.4	0
384	Outcomes of Allogeneic Transplantation in Patients Aged â‰¥ 60 Years with Acute Myeloid Leukemia in Second Complete Remission: A CIBMTR Â® Cohort Analysis. Blood, 2015, 126, 2009-2009.	1.4	0
385	Post-Hematopoietic Stem Cell Transplantation Minimal Residual Disease and Early Relapses in MDS and AML Evolving from MDS. Blood, 2015, 126, 2019-2019.	1.4	0
386	Consolidation Chemotherapy Is Not Beneficial for Adult Acute Lymphoblastic Leukemia Patients with Available Donor Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation in First Complete Remission: A CIBMTR Study. Blood, 2016, 128, 684-684.	1.4	0
387	Reversal of Low Donor Chimerism Following Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion. Blood, 2016, 128, 2215-2215.	1.4	0
388	Limitations to Receiving Allogeneic Hematopoietic Cell Transplantation for Treatment of Acute Myeloid Leukemia: A Large Multi-Center Prospective Longitudinal Observational Study. Blood, 2018, 132, 1388-1388.	1.4	0
389	Predictors of 90-Day Mortality after Admission to Intensive Care Unit (ICU) in Patients with Acute Myeloid Leukemia (AML): Application of a Novel, Recently Validated AML-Specific Risk Model. Blood, 2018, 132, 3986-3986.	1.4	0
390	Reduced Intensity Conditioning (RIC) Regimens Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia (AML): A Comparison of Fludarabine/Busulfan (FB) and Fludarabine/Melphalan (FM) Based Regimens from the CIBMTR. Blood, 2018, 132, 3456-3456.	1.4	0
391	Pre-Transplant Monocytic Myeloid-Derived Suppressor Cell Frequency Has No Prognostic Role for Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in Remission. Blood, 2018, 132, 5255-5255.	1.4	0
392	Myeloablative Conditioning Is Preferred for Allogeneic Transplantation of Acute Myeloid Leukemia and Myelodysplastic Syndromes with Low/Intermediate but Not High Disease Risk Index. Blood, 2019, 134, 4603-4603.	1.4	0
393	Comparative Analysis of Total Body Irradiation (TBI)-Based and Non-TBI-Based Myeloablative Conditioning for Acute Myeloid Leukemia in Remission with and without Measurable Residual Disease. Blood, 2019, 134, 321-321.	1.4	0
394	Sirolimus Combined with Cyclosporine (CSP) and Mycophenolate Mofetil (MMF) As Graft-Vs-Host Disease (GVHD) Prophylaxis after Nonmyeloablative (NMA) Hematopoietic Cell Transplantation (HCT) Using HLA Class I or Class II Antigen Mismatched Donors: Results from a Phase II Multi-Center Trial. Blood, 2019, 134, 369-369.	1.4	0